Oncology
Cholangiocarcinoma Just Made FGFR2 Testing Harder to Ignore
FDA has approved lirafugratinib for previously treated FGFR2 fusion- or rearrangement-positive advanced cholangiocarcinoma. Nearly half of patients responded. None of that matters if the alteration is never looked for.
Pancreatic Cancer’s ADC Moment Will Live or Die by the Biomarker
KRAS Has a New Contender. It Still Has to Earn Its Place.
China’s Biliary-Cancer Bet Has a Global Access Problem
A CE Mark Is Not Access
ALS Needs Proof, Not Just Another Biomarker
The Transplant Is Not the Finish Line
Chemo Shortages Are Back. So Is Rationing.
For Cancer That Reaches the CNS, a Payer Opens a Door
Europe Opens Another Lung Cancer Door to China-Origin Immunotherapy
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Oncology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases